ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
x/twitter facebook linkedin bluesky youtube instagram iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Diagnostic Oncology

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens Following Neoadjuvant Therapies

Sanja Dacic
+more
on: September 29, 2020In: Diagnostic Oncology, Evolving Standards of Care
IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens
            Following Neoadjuvant Therapies

Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more


PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

on: April 15, 2020In: Diagnostic Oncology
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee

By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more

Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

on: February 12, 2020In: Diagnostic Oncology
Tumor Mutation Burden: Evolution of a Controversial Biomarker From the Pathologist’s Perspective

By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more

PD-L1 in Cytology Specimens

on: December 10, 2019In: Diagnostic Oncology
PD-L1 in Cytology Specimens

By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer […] Read more

Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

on: November 11, 2019In: Diagnostic Oncology
Global Survey for Pathologists on PD-L1 Testing: Moving Toward Standardization

By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […] Read more

Special Session to Honor Dr. Adi Gazdar

on: August 13, 2019In: Diagnostic Oncology
Special Session to Honor Dr. Adi Gazdar

By Ignacio Wistuba, MD, and John Minna, MD Posted: August 14, 2019 Dr. Adi Gazdar was a scientific pioneer, a groundbreaking pathologist, a loyal friend, and an inspiring mentor. Dr. Gazdar […] Read more

Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

on: May 27, 2019In: Diagnostic Oncology
Ki-67 in Pulmonary Neuroendocrine Tumors: Where Do We Stand?

By Anja C. Roden, MD, and Natasha Rekhtman, MD, PhD Posted: May 27, 2019 Dr. Anja C. Roden Pulmonary neuroendocrine tumors are classified according to the World Health Organization into typical […] Read more

The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung Cancer

on: April 04, 2019In: Diagnostic Oncology
The IASLC Pathology Committee Recommendations for the Use of Diagnostic Immunohistochemistry in Lung
            Cancer

By Andre L. Moreira, MD Posted: April 1, 2019 Most of the progress in thoracic oncology is in the treatment of patients with NSCLC. The determination of subtypes of NSCLC, namely […] Read more

Diagnostic Oncology: Reports from the IASLC Pathology Committee

on: February 25, 2019In: Diagnostic Oncology
Diagnostic Oncology: Reports from the IASLC Pathology Committee

By Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE Posted: March 1, 2019  There was a time, remembered by us older pathologists, when the image of pathology was that of a […] Read more

The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?

on: February 25, 2019In: Diagnostic Oncology
The Rising Cost of Lung Cancer Therapies: What Are the Global Implications?

By Doreen A. Ezeife, MD, FRCPC; Malcolm Ryan; and Natasha B. Leighl, MD, MMSc, FRCPC, FASCO Posted: March 1, 2019 Dramatic improvements in lung cancer outcomes can be attributed to […] Read more

123

SEARCH ILCN

Archives

PROVIDER RESOURCES

MARIPOSA OS Data Confirms Improved Efficacy for Amivantamab Plus Lazertinib in the First Line for EGFR-mutated NSCLC

INDUSTRY SUPPORTED


COCOON’s Prophylactic Regimen Resulted in Decreased Incidence and Severity of Dermatologic-related Adverse Events

INDUSTRY SUPPORTED

POPULAR ARTICLES

Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2024 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy